All In Biotech

BLA 018780 · Lilly

Humulin R Pen

Insulin Recombinant Human, Insulin Human · Injection, Subcutaneous · Insulin

Novel

Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Oct 28, 1982

Approved uses

3

Original approval plus efficacy supplements

Registered trials

100

15 Phase 3, 0 recruiting

FAERS reports

20,477

14,713 serious, 2,078 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2026.

HUMULIN R U-500 is a concentrated human insulin indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day. HUMULIN ® R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day. ( 1 ) Limitation of Use: The safety and efficacy of HUMULIN R U-500 used in combination with other insulins has not been determined. The safety and efficacy of HUMULIN R U-500 delivered by continuous subcutaneous infusion has not been determined. ( 1.1 ) 1.1 Limitation of Use The safety and efficacy of HUMULIN R U-500 used in combination with other insulins has not been determined. The safety and efficacy of HUMULIN R U-500 delivered by continuous subcutaneous infusion has not been determined.

Mechanism: Regulation of glucose metabolism is the primary activity of insulins, including HUMULIN R U-500. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 25, 2011 Supplement 120 · Efficacy LabelLetter
  • Mar 31, 1994 Supplement 42 · Efficacy
  • Oct 28, 1982 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • HUMULIN R PEN · INSULIN RECOMBINANT HUMAN 100 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter
  • HUMULIN R · INSULIN RECOMBINANT HUMAN 100 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter
  • HUMULIN R · INSULIN HUMAN 10000 UNITS/20ML (500 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • HUMULIN R KWIKPEN · INSULIN HUMAN 1500 UNITS/3ML (500 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased4,701
  • blood glucose decreased1,664
  • drug ineffective1,594
  • hypoglycaemia1,033
  • wrong technique in product usage process875
  • nausea835
  • diarrhoea820
  • dyspnoea795
  • incorrect dose administered739
  • weight decreased695
  • fall687
  • vomiting673

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004619
2005706
2006634
2007402
2008426
2009623
2010636
2011615
2012665
2013555
2014740
20152,669
20161,018
20171,067
20181,142
20191,126
20201,087
20211,063
20221,155
20231,016
2024960
2025944
2026609

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humulin R (Insulin Regular, Human)

2024 spending

$20.2M

Beneficiaries

60,691

207,421 claims

Per beneficiary

$333

$4.01 per unit

View as table
YearSpending
2020$63,906,594
2021$60,920,819
2022$55,393,432
2023$52,271,366
2024$20,223,572

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Eli Lilly · Also marketed as Humulin R, Humulin R Kwikpen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.